1.41
price up icon7.63%   0.10
after-market Dopo l'orario di chiusura: 1.29 -0.12 -8.51%
loading
Precedente Chiudi:
$1.31
Aprire:
$1.5
Volume 24 ore:
48.22M
Relative Volume:
619.59
Capitalizzazione di mercato:
$6.10M
Reddito:
$960.60K
Utile/perdita netta:
$-7.10M
Rapporto P/E:
-0.1865
EPS:
-7.56
Flusso di cassa netto:
$-8.00M
1 W Prestazione:
+6.02%
1M Prestazione:
-25.40%
6M Prestazione:
-47.68%
1 anno Prestazione:
-42.91%
Intervallo 1D:
Value
$1.31
$1.88
Intervallo di 1 settimana:
Value
$1.26
$1.88
Portata 52W:
Value
$1.26
$14.83

Soligenix Inc Stock (SNGX) Company Profile

Name
Nome
Soligenix Inc
Name
Telefono
609-538-8200
Name
Indirizzo
29 EMMONS DRIVE, PRINCETON
Name
Dipendente
16
Name
Cinguettio
@Soligenix_Inc
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
SNGX's Discussions on Twitter

Confronta SNGX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SNGX
Soligenix Inc
1.41 6.10M 960.60K -7.10M -8.00M -7.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Soligenix Inc Stock (SNGX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2020-07-28 Downgrade Dawson James Buy → Neutral
2018-01-31 Downgrade H.C. Wainwright Buy → Neutral
2017-08-14 Reiterato Maxim Group Buy
2017-07-17 Iniziato H.C. Wainwright Buy

Soligenix Inc Borsa (SNGX) Ultime notizie

pulisher
Jun 17, 2025

Soligenix Inc. Advances in Treatment for Behçet’s Disease with SGX945 - citybuzz -

Jun 17, 2025
pulisher
Jun 17, 2025

Soligenix (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease - The Globe and Mail

Jun 17, 2025
pulisher
Jun 16, 2025

Behcet's Disease Market Growth to Accelerate in Forecast Period - openPR.com

Jun 16, 2025
pulisher
Jun 14, 2025

Cutaneous T-cell Lymphoma Market on Track for Major Expansion by 2034, According to DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG, oligenix, Ligand Pharma - Barchart.com

Jun 14, 2025
pulisher
Jun 13, 2025

True North Commercial REIT Announces June 2025 Distribution - The Globe and Mail

Jun 13, 2025
pulisher
Jun 12, 2025

Soligenix Inc. (NASDAQ: SNGX) Makes Strides in Rare Disease Treatments with Upcoming Clinical Trial Results - citybuzz -

Jun 12, 2025
pulisher
Jun 12, 2025

Silicon Valley - FinancialContent

Jun 12, 2025
pulisher
Jun 09, 2025

Soligenix (NASDAQ: SNGX) Offers Hope on the Horizon with HyBryte(TM) Treatment Targeting CTCL - Barchart.com

Jun 09, 2025
pulisher
Jun 06, 2025

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials | SNGX Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials - GlobeNewswire

Jun 06, 2025
pulisher
Jun 04, 2025

Soligenix Inc. (SNGX) Showcases Promising HyBryte Results in CTCL Treatment Through New Podcast - citybuzz -

Jun 04, 2025
pulisher
Jun 04, 2025

Soligenix (NASDAQ: SNGX) Highlights HyBryte Progress in CTCL via New Podcast Featuring Dr. Ellen Kim - Barchart.com

Jun 04, 2025
pulisher
May 27, 2025

Soligenix (NASDAQ: SNGX) Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics - Barchart.com

May 27, 2025
pulisher
May 27, 2025

Vaccine Contract Manufacturing Market Is Booming Worldwide | - openPR.com

May 27, 2025
pulisher
May 27, 2025

Galaxy Digital Inc. Announces Public Offering of Common Stock - The Globe and Mail

May 27, 2025
pulisher
May 23, 2025

Soligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results In Rare Cancer Trial - Barchart.com

May 23, 2025
pulisher
May 23, 2025

Stocks in play: Brookfield Corporation - The Globe and Mail

May 23, 2025
pulisher
May 23, 2025

Soligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer Trial - The Globe and Mail

May 23, 2025
pulisher
May 22, 2025

Chemung Financial Corporation Announces Quarterly Dividend - The Globe and Mail

May 22, 2025
pulisher
May 22, 2025

Soligenix’s HyBryte Shows Promise in Rare Cancer Treatment - citybuzz -

May 22, 2025
pulisher
May 20, 2025

Soligenix (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results - The Globe and Mail

May 20, 2025
pulisher
May 20, 2025

/R E P E A T -- Scotiabank to Announce Second Quarter 2025 Results/ - The Globe and Mail

May 20, 2025
pulisher
May 20, 2025

Public market insider selling at Sprott (SII) - The Globe and Mail

May 20, 2025
pulisher
May 19, 2025

Photodynamic Therapy Market Trends Report 2025-2033, Competitive Analysis of Gladerma, Sun Pharma, Biofrontera, Lumibird, Bausch Health, Soligenix, Modulight, and Theralase TechnologiesResearchAndMarkets.com | FinancialContent - FinancialContent

May 19, 2025
pulisher
May 18, 2025

Zacks Small Cap Predicts Reduced Earnings for Soligenix - Defense World

May 18, 2025
pulisher
May 16, 2025

Zacks Research Issues Business Update as Soligenix (NASDAQ: SNGX) Continues Enrollment in Confirmatory Phase 3 HyBryte Trial - The Globe and Mail

May 16, 2025
pulisher
May 16, 2025

Oral Mucositis Drugs Market Set to Witness Significant Growth - openPR.com

May 16, 2025
pulisher
May 15, 2025

SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte™ in CTCL… - MSN

May 15, 2025
pulisher
May 15, 2025

Soligenix Reports Q1 2025 Financial Results and Milestones - TipRanks

May 15, 2025
pulisher
May 13, 2025

SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte in CTCL - Research Tree

May 13, 2025
pulisher
May 12, 2025

Contrasting Schrödinger (NASDAQ:SDGR) and Soligenix (NASDAQ:SNGX) - Defense World

May 12, 2025
pulisher
May 10, 2025

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results - Nasdaq

May 10, 2025
pulisher
May 09, 2025

Soligenix Announces Recent Accomplishments And First Quarter 202 - GuruFocus

May 09, 2025
pulisher
May 07, 2025

Soligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast Episode - The Globe and Mail

May 07, 2025
pulisher
May 07, 2025

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc. - The Manila Times

May 07, 2025
pulisher
May 05, 2025

Geode Capital Management LLC Has $71,000 Stake in Soligenix, Inc. (NASDAQ:SNGX) - Defense World

May 05, 2025
pulisher
May 05, 2025

Soligenix Issues Interim Results For CTCL Treatment Trial 75% Response At 18 Weeks, 3 Patients Achieve Complete Response - FinancialContent

May 05, 2025
pulisher
May 02, 2025

Soligenix (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer - Barchart.com

May 02, 2025
pulisher
May 02, 2025

Soligenix (SNGX) Projected to Post Quarterly Earnings on Friday - Defense World

May 02, 2025
pulisher
Apr 30, 2025

Soligenix (NASDAQ: SNGX) Moves Forward To Strengthen The Case For HyBryte(TM) - Barchart.com

Apr 30, 2025
pulisher
Apr 30, 2025

Soligenix (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM) - The Globe and Mail

Apr 30, 2025
pulisher
Apr 25, 2025

U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com

Apr 25, 2025
pulisher
Apr 24, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 24, 2025
pulisher
Apr 24, 2025

Soligenix reports positive results in skin cancer treatment trial By Investing.com - Investing.com India

Apr 24, 2025
pulisher
Apr 24, 2025

Fireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc. - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

Soligenix reports positive results in skin cancer treatment trial - Investing.com Australia

Apr 24, 2025

Soligenix Inc Azioni (SNGX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):